Search Results - "Cakana, Andrew Z"

Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns by Chinowaita, Frank, Chaka, Wendy, Nyazika, Tinashe K, Maboreke, Tendai C, Tizauone, Emmanuel, Mapondera, Prichard, Chitsike, Inam, Cakana, Andrew Z, Mavenyengwa, Rooyen T

“…Cancer and sepsis comorbidity is a major public health problem in most parts of the world including Zimbabwe. The microbial aetiologies of sepsis and their…”
Get full text

Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial by Robinson, Donald, Orlowski, Robert Z., He, Jianming, Lam, Annette, Zhao, Ning, Cakana, Andrew Z

“…Background: The direct (medical utilization) cost of relapsed or refractory multiple myeloma (RRMM) has been documented; recent studies are now exploring…”
Get full text

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics by Moreau, Philippe, Karamanesht, Ievgenii I, Domnikova, Natalia, Kyselyova, Maryna Y, Vilchevska, Kateryna, Doronin, Vadim A, Schmidt, Alexander, Hulin, Cyrille, Leleu, Xavier, Esseltine, Dixie-Lee, Venkatakrishnan, Karthik, Skee, Donna M, Feng, Huaibao, Girgis, Suzette, Cakana, Andrew Z, Deraedt, William M, Facon, Thierry

“…Abstract 1863 The proteasome inhibitor bortezomib is approved for the treatment of multiple myeloma (MM); the recommended dose and schedule is 1.3 mg/m2…”
Get full text

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study by Coiffier, Bertrand, Li, Weimin, Henitz, Erin D, Karkera, J.D., Favis, Reyna, Gaffney, Dana, Shapiro, Alice, Theocharous, Panteli, Elsayed, Yusri A, van de Velde, Helgi, Osmanov, Evgenii A, Hong, Xiaonan, Scheliga, Adriana, Offner, Fritz C., Rule, Simon, Teixeira, Adriana C, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Zinzani, Pier Luigi, Cakana, Andrew Z, Esseltine, Dixie-Lee, Mulligan, George, Ricci, Deborah S

“…Abstract 265 Treatment goals in patients with relapsed FL are to prolong PFS and improve overall survival (OS). To optimize treatment for individual patients,…”
Get full text

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial by Miguel, Jesús F San, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios Athanasios, Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria T, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Delforge, Michel, Jiang, Bin, Mateos, María-Victoria, Anderson, Kenneth C., Esseltine, Dixie-Lee, Liu, Kevin, Deraedt, William M, Cakana, Andrew Z, van de Velde, Helgi, Richardson, Paul G.

“…Abstract 476▪FN2▪This icon denotes a clinically relevant abstract Data from the initial report of the international, multicenter, phase 3 VISTA trial…”
Get full text

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM) by Miguel, Jesús F San, Richardson, Paul G., Orlowski, Robert Z., Goldschmidt, Hartmut, Corzo, Deyanira, Satler, Carol, Esseltine, Dixie-Lee, Neuwirth, Rachel, Ponsillo, Maria, Cakana, Andrew Z, King, Jay, Deraedt, William M, Desai, Avinash, Lutska, Yana, Gifkins, Dina, Liu, Kevin, Sonneveld, Pieter

“…Abstract 2933 MM patients have a significantly increased risk of developing certain SPMs subsequent to their initial diagnosis, including a 3.49-fold increased…”
Get full text

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial by Dhawan, Ravinder, Robinson Jr, Don, Meunier, Juliette, Regnault, Antoine, Rosa, Kathleen, Cakana, Andrew Z, van de Velde, Helgi, Richardson, Paul G, San Miguel, Jesús F

“…Abstract 1881 Poster Board I-904 The impact of multiple myeloma treatment on patient-reported health-related quality of life (HRQoL) merits careful evaluation…”
Get full text

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use by Mateos, Maria-Victoria, Richardson, Paul G, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A., Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria Teresa, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Schots, Rik, Jiang, Bin, Esseltine, Dixie-Lee, Liu, Kevin, Cakana, Andrew Z, van de Velde, Helgi, Miguel, Jesús F. San

“…Abstract 3859 Poster Board III-795 The initial results of the pivotal, international, phase III VISTA trial demonstrated the superiority of bortezomib…”
Get full text